Gossypetin Prevents the Progression of Nonalcoholic Steatohepatitis by Regulating Oxidative Stress and AMP-Activated Protein Kinase
Molecular Pharmacology · 2023
DOI: 10.1124/molpharm.123.000675 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmacology, 2023. Verfasst von Eunji Oh und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, Pohang University of Science and Technology, Pohang Republic of Korea (E.O., J.L., S.C., S.W.K., K.W.J., W.S.S., S.H.G.,…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Nonalcoholic steatohepatitis (NASH) is a severe liver metabolic disorder, however, there are still no effective and safe drugs for its treatment. Previous clinical trials used various therapeutic approaches to target individual pathologic mechanisms, but these approaches were unsuccessful because of the complex pathologic causes of NASH. Combinatory therapy in which two or more drugs are administered simultaneously to patients with NASH, however, carries the risk of side effects associated with each individual drug. To solve this problem, we identified gossypetin as an effective dual-targeting agent that activates AMP-activated protein kinase (AMPK) and decreases oxidative stress. Administration of gossypetin decreased hepatic steatosis, lobular inflammation and liver fibrosis in the liver tissue of mice with choline-deficient high-fat diet and methionine-choline deficient diet (MCD) diet-induced NASH. Gossypetin functioned directly as an antioxidant agent, decreasing hydrogen peroxide and palmitate-induced oxidative stress in the AML12 cells and liver tissue of MCD diet-fed mice without regulating the antioxidant response factors. In addition, gossypetin acted as a novel AMPK activator by binding to the allosteric drug and metabolite site, which stabilizes the activated structure of AMPK. Our findings demonstrate that gossypetin has the potential to serve as a novel therapeutic agent for nonalcoholic fatty liver disease /NASH. SIGNIFICANCE STATEMENT: This study demonstrates that gossypetin has preventive effect to progression of nonalcoholic steatohepatitis (NASH) as a novel AMP-activated protein kinase (AMPK) activator and antioxidants. Our findings indicate that simultaneous activation of AMPK and oxidative stress using gossypetin has the potential to serve as a novel therapeutic approach for nonalcoholic fatty liver disease /NASH patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Life Sciences, Pohang University of Science and Technology, Pohang Republic of Korea (E.O., J.L., S.C., S.W.K., K.W.J., W.S.S., S.H.G., K-T.K.); Department of Biochemistry and Molecular Biology, Graduate S…
ORCID-Profile: Sungji Cho
Zitieren
APA
Oh, E., Lee, J., Cho, S., Kim, S. W., Won, K., Shin, W. S., Gwak, S. H., Ha, J., Jeon, S. Y., Park, J. H., Song, I. S., Thoudam, T., Lee, I. K., Kim, S., Choi, S. Y., & Kim, K. T. (2023). Gossypetin Prevents the Progression of Nonalcoholic Steatohepatitis by Regulating Oxidative Stress and AMP-Activated Protein Kinase. Molecular Pharmacology. https://doi.org/10.1124/molpharm.123.000675
Vancouver
Oh E, Lee J, Cho S, Kim SW, Won K, Shin WS, et al. Gossypetin Prevents the Progression of Nonalcoholic Steatohepatitis by Regulating Oxidative Stress and AMP-Activated Protein Kinase. Molecular Pharmacology. 2023. doi:10.1124/molpharm.123.000675
BibTeX
@article{Oh2023,
author = {Oh, Eunji and Lee, Jae and Cho, Sungji and Kim, Sung Wook and Won, Kyung and Shin, Won Sik and Gwak, Seung Hee and Ha, Joohun and Jeon, So Yeon and Park, Jin-Hyang and Song, Im-Sook and Thoudam, Themis and Lee, In-Kyu and Kim, Seonyong and Choi, Se-Young and Kim, Kyong-Tai},
title = {Gossypetin Prevents the Progression of Nonalcoholic Steatohepatitis by Regulating Oxidative Stress and AMP-Activated Protein Kinase},
journal = {Molecular Pharmacology},
year = {2023},
doi = {10.1124/molpharm.123.000675}
}
EUVIMED